Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas.
Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas.
复制标题
DOI：
10.1007/s00109-005-0700-2
复制
发表时间：
2005-11
影响因子：
4.7
通讯作者：
Collins, VP
中科院分区：
文献类型：
--
作者：
Liu, L;Bäcklund, LM;Nilsson, BR;Grandér, D;Ichimura, K;Goike, HM;Collins, VP
本研究的目的是评估评估EGFR扩增的临床价值，以及EGFR在星形胶质细胞胶质瘤中常见的5 '重排导致EGFRvIII转录。来自221个肿瘤的数据与患者生存率相关。以前的大多数研究只评估了扩增，并提供了相互矛盾的结果。扩增用Southern blots或定量PCR进行分析。通过RT-PCR检测EGFR转录本并进行测序。对一个亚组进行RNase保护实验以证实PCR结果。胶质母细胞瘤（GB）和间变性星形细胞瘤（AA）中分别有41%（65/160）和10%（4/41）存在EGFR扩增。EGFRvIII重排在54%（35/65）的GB和75%（3/4）的AA中扩增，在8%（8/95）的GB和5%（2/37）的AA中未扩增（通过RNase保护论文证实）。II级星形细胞瘤（AII）中EFGR及其转录物未见异常。在160例GB患者中，我们发现EGFR扩增或重排与年龄或生存无显著关联。我们注意到有任何EGFR异常的41例AA患者有降低生存率的趋势。这在具有EGFRvIII转录本的5例患者中最为明显（p= 0.069），但这些患者明显比没有EGFRvIII转录本的患者年龄大（p= 0.023）。所有患者均未发现EGFR异常。我们得出结论，EGFR扩增和EGFRvIII转录物的存在都不能预测常规治疗的GB患者的预后。然而，在AA中，虽然不常见，但EGFR畸变似乎与较短的生存期有关。
The aim of this study was to evaluate the clinical value of assessing EGFR amplification, and the common 5′ rearrangement of EGFR resulting in the EGFRvIII transcript in astrocytic gliomas. The data from 221 tumours was correlated with patient survival. The majority of previous studies evaluated amplification alone and have provided contradictory results. Amplification was analyzed by densitometry of Southern blots or quantitative PCR. EGFR transcripts were examined by RT-PCR and subsequent sequencing. An RNase protection assay was carried out on a subgroup to confirm the PCR results. Amplification of EGFR was found in 41% (65/160) of glioblastomas (GB), and 10% (4/41) of anaplastic astrocytomas (AA). The EGFRvIII rearrangement was identified in 54% (35/65) of GB and 75% (3/4) of AA with amplification as well as in 8% (8/95) of GB and 5% (2/37) of AA without amplification (confirmed by RNase protection essay). There were no abnormalities of the EFGR or its transcript in astrocytomas malignancy grade II (AII). We found no significant association between EGFR amplification or rearrangement and age or survival in the 160 GB patients. We noted a tendency towards decreased survival in the 41 patients with AA with any EGFR abnormality. This was most marked in the 5 cases with the EGFRvIII transcript (p=0,069) but these were significantly older than those without (p=0,023). No abnormalities of EGFR were identified in AII patients. We conclude that neither EGFR amplification nor the presence of the EGFRvIII transcript predict patient outcome in conventionally treated GB. In AA however, although uncommon, EGFR aberrations appear to be associated with shorter survival.
登录
查看更多内容
影响因子：
64.5
作者：
Lemmon MA;Schlessinger J
通讯作者：
Schlessinger J
DOI：
10.1073/pnas.130166597
发表时间：
2000-06-20
影响因子：
11.1
作者：
Sampson, JH;Crotty, LE;Bigner, DD
通讯作者：
Bigner, DD
DOI：
10.1073/pnas.232686499
发表时间：
2003-01-21
影响因子：
11.1
作者：
Jungbluth, AA;Stockert, E;Old, LJ
通讯作者：
Old, LJ
DOI：
10.1097/00005072-199812000-00005
发表时间：
1998-12-01
影响因子：
3.2
作者：
Liu, L;Ichimura, K;Collins, VP
通讯作者：
Collins, VP
DOI：
10.1093/jnen/63.7.700
发表时间：
2004-07-01
影响因子：
3.2
作者：
Aldape, KD;Ballman, K;James, CD
通讯作者：
James, CD